Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Nexium Data Shows 47% Of Scripts Are First-Time PPI Users

Executive Summary

Nexium sales data from the U.K. and Germany shows that 47% of prescriptions are for patients new to proton pump inhibitors, AstraZeneca CEO Tom McKillop, PhD, reported at the company's year-end earnings conference in London Feb. 8.

You may also be interested in...



AstraZeneca Nexium Relying On Healing Rate, Symptom Maintenance

AstraZeneca's efforts to build a superiority claim for the proton pump inhibitor Nexium hinge on three elements of labeling.

AstraZeneca Nexium Relying On Healing Rate, Symptom Maintenance

AstraZeneca's efforts to build a superiority claim for the proton pump inhibitor Nexium hinge on three elements of labeling.

Wholesaler Forward-Buying Is Back, J&J Says; Rx Price Increases Pick Up

Johnson & Johnson is seeing an upward trend in forward-buying by wholesalers, CFO Robert Darretta told analysts Jan. 23 in New York City.

Related Content

UsernamePublicRestriction

Register

PS037318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel